These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 8804017

  • 1. beta 2-Microglobulin amyloidosis: effect of ESRF treatment modality and dialysis membrane type.
    Van Ypersele de Strihou C.
    Nephrol Dial Transplant; 1996; 11 Suppl 2():147-9. PubMed ID: 8804017
    [No Abstract] [Full Text] [Related]

  • 2. Beta 2-microglobulin associated amyloidosis and therapy with high flux hemodialysis membranes.
    Floege J, Koch KM.
    Clin Nephrol; 1994 Jul; 42 Suppl 1():S52-6. PubMed ID: 7923985
    [No Abstract] [Full Text] [Related]

  • 3. [Amyloidosis of the dialysis patient].
    van Ypersele de Strihou C.
    Bull Mem Acad R Med Belg; 1988 Jul; 143(10-12):456-65; discussion 465-7. PubMed ID: 3077074
    [No Abstract] [Full Text] [Related]

  • 4. [Beta 2-microglobulin--its role in renal failure and hemodialysis therapy].
    Czyz W, Szepietowski T.
    Postepy Hig Med Dosw; 1992 Jul; 46(2):209-38. PubMed ID: 1470582
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Beta 2-microglobulin-related amyloidosis in patients receiving chronic hemodialysis.
    Gejyo F, Homma N, Maruyama H, Arakawa M.
    Contrib Nephrol; 1988 Jul; 68():263-9. PubMed ID: 3069321
    [No Abstract] [Full Text] [Related]

  • 8. [Long-term management of dialysis patients. II. Beta 2-microglobulin associated amyloidosis and acquired cystic kidney disease].
    Floege J, Segerer S, Schäffer J, Koch KM.
    Internist (Berl); 1999 Jan; 40(1):64-9. PubMed ID: 10086302
    [No Abstract] [Full Text] [Related]

  • 9. [Prevention of dialysis-related amyloidosis].
    Yamamoto S, Gejyo F, Kazama JJ.
    Nihon Rinsho; 2004 Jun; 62 Suppl 6():353-6. PubMed ID: 15250323
    [No Abstract] [Full Text] [Related]

  • 10. Persistence of dialysis amyloid after renal transplantation. A case report.
    Sethi D, Brown EA, Cary NR, Woodrow DF, Gower PE.
    Am J Nephrol; 1989 Jun; 9(2):173-4. PubMed ID: 2662775
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. High-efficiency dialysis with PMMA dialyzers: treatment dose delivery and long-term results.
    David S, Cambi V.
    Contrib Nephrol; 1999 Jun; 125():96-110. PubMed ID: 9895434
    [No Abstract] [Full Text] [Related]

  • 14. Amyloidosis in patients with end-stage renal failure: uraemia associated or dialysis related?
    Davison AM.
    Contrib Nephrol; 1995 Jun; 113():92-100. PubMed ID: 7712726
    [No Abstract] [Full Text] [Related]

  • 15. Is beta 2-microglobulin a mediator of bone disease?
    Sprague SM, Popovtzer MM.
    Kidney Int; 1995 Jan; 47(1):1-6. PubMed ID: 7731134
    [No Abstract] [Full Text] [Related]

  • 16. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure.
    Miyata T.
    Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608
    [Abstract] [Full Text] [Related]

  • 17. Dialysis-related amyloidosis and clinical significance of extracorporeal removal of beta2-microglobulin.
    Gejyo F, Suzuki S, Arakawa M.
    Ther Apher; 1997 May; 1(2):126-8. PubMed ID: 10225756
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Dialysis amyloidosis and beta-2-microglobulin].
    Sulková S, Votruba T.
    Cas Lek Cesk; 1989 Jan 13; 128(3):68-73. PubMed ID: 2655913
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.